NCT00882583View on ClinicalTrials.gov

A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC

PHASE1TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Head and Neck Cancer
Interventions
DRUG

Cetuximab

single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8

DRUG

Dasatinib

Oral Dasatinib Days 8 through 64.

DRUG

Cisplatin

Q 3 weeks (Days 15, 36 and 57): +/- 3 Days

RADIATION

Radiation Therapy

Standard Radiation Therapy.

Trial Locations (2)

21287

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

43210

Ohio State University Medical Center, Columbus

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00882583 - A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC | Biotech Hunter | Biotech Hunter